Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

AnisoPlate High-throughput production of anisotropic 3D human tissue models

Coordinator
Dwi Leibniz-Institut Fur Interaktive Materialien eV, Germany
Runs
1 September 2024 to 28 February 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101150675

What the project is doing

In the project's own words, from its summary on CORDIS.

The limitations of current in vitro tissue models pose a significant challenge in drug discovery and personalized medicine, leading to inefficiencies and unreliability in preclinical testing. These shortcomings result in high costs and prolonged timelines for drug development, straining resources and delaying patient access to innovative treatments. This is mainly due to the currently available cell and tissue models based on flat petri dishes and isotropic hydrogels, which fail to accurately represent the anisotropic structures found in native tissues leading to unreliable preclinical results.

Animal models, although considered the gold standard, raises ethical concerns and introduces significant differences compared to human tissues. To address these shortcomings, we have developed a hydrogel system that can be used to fabricate 3D culture models with oriented structures using AnisoPlate. The AnisoPlate is a handheld magnetic device for providing the required external magnetic field in culture plates for the orientation of the rods.

The hydrogel system consists of rod-shape elements that are made magneto-responsive by encapsulating superparamagnetic iron oxide nanoparticles (SPIONs). When exposed to low external magnetic fields (in the millitesla range) provided by the AnisoPlate, these rods align in the direction of the field and can be assembled into 3D macroporous oriented constructs mimicking the anisotropic architecture of human tissues. Our solution holds promise not only for researchers in drug discovery, tissue engineering, and regenerative medicine but also for pharmaceutical industries seeking physiologically relevant in vitro models for more accurate preclinical studies, contract research organizations (CROs) aiming to enhance their efficacy in high-throughput screening, and ultimately patients who stand to benefit from accelerated and improved drug development processes leading to innovative treatments.

Topics

Who is involved

OrganisationCityCountryRole
Dwi Leibniz-Institut Fur Interaktive Materialien eVAachenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI